Navigation Links
CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
Date:8/27/2007

SAN DIEGO, Aug. 27 /PRNewswire-FirstCall/ -- CryoCor, Inc. (Nasdaq: CRYO), a medical device company focused on the treatment of cardiac arrhythmias, announced today the completion of enrollment of its pivotal clinical study for the treatment of atrial fibrillation.

Ed Brennan, Ph.D. Chief Executive Officer of CryoCor, said, "This is a major milestone for CryoCor, being the first company to complete enrollment in a randomized pivotal study for the use of ablation for the treatment of atrial fibrillation. Completion of enrollment confirms our lead over other companies conducting atrial fibrillation ablation pivotal trials and brings us one step closer to our goal of bringing our product to market for the treatment of atrial fibrillation. With the recent approval of our cryoablation system for the treatment of right atrial flutter, in the fourth quarter, we will begin placing our system at high volume ablation centers across the U.S., familiarizing physicians with our system and establishing our installed base of consoles in anticipation of approval for the treatment of atrial fibrillation in 2009."

Helen Barold, M.D. Chief Medical Officer of CryoCor, said, "I am very pleased with the progress we have made with this study and look forward to fully analyzing the data. We continue to see an excellent safety profile for our cryoablation device and expect to file a PMA in late 2008. At this point we will begin our non-randomized continued access protocol in which patients will be enrolled into the ablation arm. "

CryoCor has enrolled over 170 patients in its pivotal clinical study and will complete a 12-month follow up for each patient.

About CryoCor

CryoCor is a medical technology company that has developed and manufactures a disposable catheter system based on its proprietary cryoablation technology for the minimally invasive treatment of cardiac arrhythmias. The Company's product, the CryoCor Cardiac Cryoablation System, or the Cryoa
'/>"/>

SOURCE CryoCor, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of C1-Esterase Inhibitor for Hereditary Angioedema
2. Celsion Completes Enrollment in Phase I Liver Cancer Study
3. LANI completes Phase I in Japan and to commence Phase I in UK
4. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
7. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
8. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
9. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
10. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
11. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2008)... ATLANTA, May 12 /- Geo...nta- based HIV/AIDS vaccine development,company, a...ion common,stock purchase agreement with Fusion Ca...investor., The Company may sell up to $10 million...o time over a 25-month period after the Securities...
(Date:5/12/2008)... ANN ARBOR, Mich., May 12 /- Velc...mpletion of a first-in-man clinical trial for,its ...stigating as a,treatment for Rheumatoid Arthritis ...ical studies, VEL-0230 proved to be a powerful,ant...mation and inhibits,bone loss. Taken together, the...
(Date:5/12/2008)... Provides the Optimal Combination of Scaffoldi... Conformability, TEL AVIV, Israel, May 12 /PRNews...received CE Mark for its Presillion(TM) CoCr Coron...rtery lesions with a technologically,innovative fl...preserves the superb scaffolding the unprecedented...
(Date:5/12/2008)... Presentation of Phase 1 Clinical Data of MDX-1100... 2008, PRINCETON, N.J., May 12 /PRNewswi...nounced today that it has initiated the Phase 2 cl...man monoclonal antibody that,targets CXCL10 (also ...eumatoid arthritis (RA). MDX-1100 could potentiall...
Breaking Medicine Technology:GeoVax Secures $10 Million Financing Commitment 2GeoVax Secures $10 Million Financing Commitment 3Velcura Therapeutics, Inc. Reports Successful Phase 1 Clinical Trial of Novel Bone Disease Therapy 2Medinol Receives CE Mark for Presillion(TM) Cobalt Chromium Coronary Stent on Rx System, an Advanced Evolution of the NIR(R) Family of Stents 2Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis 2Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis 3Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis 4What are the causes and consequences of childhood obesity 3F 1889 1Story ideas from the Journal of Biological Chemistry 1885 1Study examines decision making deficits in older adults 9510 1Study examines decision making deficits in older adults 9510 2Study examines decision making deficits in older adults 9510 3Edwards Lifesciences Completes Sale of LifeStent Product Line to Bard 9507 1
(Date:5/12/2008)...ire-FirstCall/ -- (Nasdaq: WHRT, TSX:,WHT) World H...") announced,that the Toronto Stock Exchange ("TSX...g the eligibility for continued listing on the TSX... 709 and 710(a) of the TSX Company,Manual. This re...and,operating results, more specifically whether t...
(Date:5/12/2008)...rstCall/ -- Allied Healthcare Products,Inc. (Nasd... the third,quarter ending March 31 fell 64 percent...are, to about $100,000 in the current quarter, or ...creased by about $240,000 compared to the,third qu...and labor costs,this fiscal year eroded margins an...
(Date:5/12/2008)...Newswire-FirstCall/ -- China Yingxia,International... or "the,Company"), a leading provider in the nutr...ufacture and distribution of organic nutritional f...cts in the People,s Republic,of China ("PRC"), ann...iday, May 16, 2008, at 10:00 a.m. EDT, to discuss ...
(Date:5/12/2008)...RME TSX: COM, VANCOUVER, May 12 /PRNewswire-First... COM) today announced that it will report financia...ernoon of Tuesday, May 13,2008. Cardiome will hol...ern (1:30pm Pacific) on that day to discuss the re...l 416-641-6117 or,866-299-6655. There will be a se...
Breaking Medicine News(10 mins):Health News:WorldHeart Notified of TSX Delisting Review 2Health News:Allied Healthcare Net Falls on Manufacturing Delays 2Health News:Allied Healthcare Net Falls on Manufacturing Delays 3Health News:Allied Healthcare Net Falls on Manufacturing Delays 4Health News:Allied Healthcare Net Falls on Manufacturing Delays 5Health News:China Yingxia International, Inc. Announces Conference Call to Discuss First Quarter 2008 Results 2Health News:Cardiome To Release 2008 First Quarter Results 2Health News:Cardiome To Release 2008 First Quarter Results 3Health News:Cardiome To Release 2008 First Quarter Results 4
...aste to the brain and its neurons. So it is not yo...rd but just love the chocolate.// The study that d...osophila by Kristin Scott and colleagues. Accordi... has special cells which detect specific tastes. M...
...-Appel (Ecole des Hautes Etudes en Sciences Social... birth rate when man discovered agriculture.// Thi...lithic period. Anthropologists studied 60 prehist...fact that agriculture played a very important role...
...problems and asthma if they are taught to swim bef...he professor of toxicology at Belgium's Catholic U...els of the irritant trichloramine were 50% higher ...ult pools, and that his recent study of 341 school...
... recommended a report which makes possible the pat...tation with out referral from the physician. // T... has welcomed the report as they feel that the mov...atients in reaching a specialist and a consultatio...
Other Medicine News:Health News:Children Face Risk While Swimming 2
...new standard in the field of hammertoe implants wi...ical grade silicone, these durable and lasting imp... flexibility while maintaining correct toe length ...stiffnesses. Lengths are determined by the surgeon...
...Nerve Electrodes provide direct cranial nerve moni... circumferential design provides sensitive contact...l-time recordings. This unique approach provides y... acoustic neuromas, microvascular decompressions, ...
State-of-the-art sleep recording and analysis
... offers the capability to acquire images in near-r...ess and Contrast levels, Auto-windowing, Image Man...e tube's Rhodium spectrum which is best adapted to...on flat panel digital detector, which is the resul...
Medicine Products: